Biogen Inc. BIIB, +2.64% shares fell more than 6% in the extended session Tuesday after the Centers for Medicare and Medicaid Services, which oversees the Medicare program, said it plans to cover the biotech’s controversial Alzheimer’s drug Aduhelm and future others like it only in certain instances. CMS’s proposal is that Food and Drug Administration-approved […]